当前位置: X-MOL 学术Nat. Rev. Drug. Disc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lidia Fonseca.
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2020-06-16 , DOI: 10.1038/d41573-020-00114-z
Asher Mullard

Last year, Pfizer joined the growing ranks of pharmaceutical firms with a digital strategy leader on their executive management teams. Lidia Fonseca, Pfizer’s first Chief Digital & Technology Officer, stepped into this role with a broad remit to set the company’s digital goals in drug discovery and development, operational processes and manufacturing, product sales, patient-facing experiences and more. No small task before COVID-19, the global pandemic has now forced companies to embrace digital tactics more than ever. Fonseca spoke with Asher Mullard about Pfizer’s pre-COVID-19 digital priorities, and how the pandemic has changed things.

中文翻译:

莉迪亚·丰塞卡(Lidia Fonseca)。

去年,辉瑞(Pfizer)在其执行管理团队中加入了数字策略领导者,从而加入了越来越多的制药公司行列。辉瑞公司的首位首席数字技术官Lidia Fonseca广泛担任这一职务,以设定公司在药物发现和开发,运营流程和制造,产品销售,面向患者的体验等方面的数字化目标。在COVID-19之前,这可不是一件容易的事,全球大流行现在迫使公司比以往任何时候都更喜欢采用数字策略。丰塞卡与Asher Mullard谈及了辉瑞公司在COVID-19之前的数字优先事项,以及该流行病如何改变了事情。
更新日期:2020-06-16
down
wechat
bug